{"id":"NCT01554956","sponsor":"Kedrion S.p.A.","briefTitle":"Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients","officialTitle":"A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-05-22","primaryCompletion":"2014-04-25","completion":"2020-12-04","firstPosted":"2012-03-15","resultsPosted":"2023-01-25","lastUpdate":"2023-01-25"},"enrollment":12,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ligneous Conjunctivitis"],"interventions":[{"type":"BIOLOGICAL","name":"Human Plasminogen","otherNames":[]}],"arms":[{"label":"Human Plasminogen","type":"EXPERIMENTAL"}],"summary":"Kedrion Human Plasminogen, a sterile human plasma-derived plasminogen preparation for topical ocular use will be evaluated for the indication of treatment of ligneous conjunctivitis.\n\nKB046 will be an open-label, historically controlled clinical trial. At least 10 subjects with ligneous conjunctivitis, for approximately 20 eyes, will be treated and assessed. All subjects will receive the investigational medicinal product (IMP) for 12 to 48 weeks, with a possibility for extended treatment (Continuation segment)","primaryOutcome":{"measure":"Percentage of Success to Prevent Pseudomembranes Relapse","timeFrame":"The prevention of pseudomembranes relapse was assessed during Segment 2, after initial total regression at the end of Segment 1 (Group 1A) or after surgical excision (Group 1B) up to 21 weeks from the study start.","effectByArm":[{"arm":"Group 1A_mITT","deltaMin":75,"sd":null},{"arm":"Group 1B_mITT","deltaMin":81.8,"sd":null},{"arm":"Group 1A_PP","deltaMin":100,"sd":null},{"arm":"Group 1B_PP","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":3,"countries":["United States","Italy"]},"refs":{"pmids":["35346720"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":4},"commonTop":["Pyrexia","Cough","Antibody test positive","Rhinorrhoea","Ear infection"]}}